search
Back to results

IV Paracetamol, Dexketoprofen or Morphine for the Treatment of Low Back Pain

Primary Purpose

Low Back Pain

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
paracetamol
morphine
Dexketoprofen
Paracetamole
Sponsored by
Pamukkale University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Low Back Pain focused on measuring Low back pain, paracetamol, dexketoprofen, morphine

Eligibility Criteria

16 Years - 55 Years (Child, Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Adults (aged 16 to 55 years) with acute low back pain were eligible for inclusion in the study- -

Exclusion Criteria:

  • Exclusion criteria included known allergy or contraindication to morphine, paracetamol,dexketoprofen or any opioid analgesic
  • Hemodynamic instability
  • Fever (temperature >38°C [100.4°F])
  • Evidence of peritoneal inflammation
  • Documented or suspected pregnancy
  • Known or suspected aortic dissection or aneurysm, lombar disc hernia
  • Use of any analgesic within 6 hours of ED presentation
  • Previous study enrollment.
  • Patients with known renal, pulmonary, cardiac, or hepatic failure, as well as those with renal transplantation, were also excluded.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Experimental

    Arm Label

    morphine

    Paracetamole, dexketoprofen

    Arm Description

    Paracetamole, dexketoprofen

    Outcomes

    Primary Outcome Measures

    Reduction in visual analogue scale
    The pain of the study subjects was measured after 15th and 30th minutes later after the study drug administered

    Secondary Outcome Measures

    Adverse events.
    30 minutes after the study drug administered

    Full Information

    First Posted
    August 22, 2011
    Last Updated
    August 22, 2011
    Sponsor
    Pamukkale University
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT01422291
    Brief Title
    IV Paracetamol, Dexketoprofen or Morphine for the Treatment of Low Back Pain
    Official Title
    Pamukkale University Medical School,Dept. of Emergency Medicine
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2011
    Overall Recruitment Status
    Completed
    Study Start Date
    January 2011 (undefined)
    Primary Completion Date
    July 2011 (Actual)
    Study Completion Date
    July 2011 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Pamukkale University

    4. Oversight

    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This randomized, controlled trial evaluates the analgesic efficacy and safety of intravenous single-dose paracetamol, dexketoprofen and morphine for the treatment of low back pain.
    Detailed Description
    Study Design and Setting: This is a single-center, prospective, randomized, double-blind, clinical trial performed in an ED of a tertiary care hospital with annual census of approximately 37.000 visits. The local ethics committee approved the study. Interventions: We conducted a randomized, controlled clinical trial comparing single intravenous doses of paracetamol (1 g), dexketoprofen (50 mg) and morphine (0.1 mg/kg) for patients presenting to the emergency department (ED) with suspected low back pain. Subjects with inadequate pain relief at 30 minutes received rescue fentanyl (0.75 microg/kg). We compared changes in pain intensity 30 minutes after treatment. Methods of Measurements: Subjects reported pain intensity on both a 100-mm visual analogue scale (limited by 'no pain' and 'the worst pain') and a 4-point verbal rating scale (no pain, mild, moderate, or severe pain) just before the drug administration, 15th minutes and 30th minutes after the study drug administration. The demographic features of study patients and adverse effects, nausea, vomiting, dizziness, vertigo, headache, hypotension, altered mental status, allergic reaction, itching, urinary retention, thoracic rigidity, respiratory depression and dry mouth, were recorded to the study form. Outcome Measures The primary outcome measure was the pain reduction in VAS and VRS at 15th and 30th minutes. Secondary outcome measures were the need for rescue drug and the presence of any adverse event. Primary Data Analysis: The present study was planned as a superiority trial. When the 20 mm difference in VAS is accepted as clinically significant and the standard deviation is accepted as 25 mm, 35 patients are needed with each group with 95% power. All the analysis were implemented according to the intention to treat analysis. The precise of differences between time intervals within groups and between groups and statistical significance were expressed by 95% confidence intervals (95% CI).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Low Back Pain
    Keywords
    Low back pain, paracetamol, dexketoprofen, morphine

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare Provider
    Allocation
    Randomized
    Enrollment
    120 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    morphine
    Arm Type
    Active Comparator
    Arm Title
    Paracetamole, dexketoprofen
    Arm Type
    Experimental
    Arm Description
    Paracetamole, dexketoprofen
    Intervention Type
    Drug
    Intervention Name(s)
    paracetamol
    Other Intervention Name(s)
    Perfalgan
    Intervention Description
    1 gr
    Intervention Type
    Drug
    Intervention Name(s)
    morphine
    Other Intervention Name(s)
    Morphine CHL 0.01 gr
    Intervention Description
    0.1mg/kg intravenous in 100 ml serum physiologic
    Intervention Type
    Drug
    Intervention Name(s)
    Dexketoprofen
    Other Intervention Name(s)
    Arveles
    Intervention Description
    50 mg
    Intervention Type
    Drug
    Intervention Name(s)
    Paracetamole
    Other Intervention Name(s)
    Perfalgan
    Intervention Description
    1 gr
    Primary Outcome Measure Information:
    Title
    Reduction in visual analogue scale
    Description
    The pain of the study subjects was measured after 15th and 30th minutes later after the study drug administered
    Time Frame
    15 minutes interval
    Secondary Outcome Measure Information:
    Title
    Adverse events.
    Description
    30 minutes after the study drug administered
    Time Frame
    30 minutes after

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    16 Years
    Maximum Age & Unit of Time
    55 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Adults (aged 16 to 55 years) with acute low back pain were eligible for inclusion in the study- - Exclusion Criteria: Exclusion criteria included known allergy or contraindication to morphine, paracetamol,dexketoprofen or any opioid analgesic Hemodynamic instability Fever (temperature >38°C [100.4°F]) Evidence of peritoneal inflammation Documented or suspected pregnancy Known or suspected aortic dissection or aneurysm, lombar disc hernia Use of any analgesic within 6 hours of ED presentation Previous study enrollment. Patients with known renal, pulmonary, cardiac, or hepatic failure, as well as those with renal transplantation, were also excluded.

    12. IPD Sharing Statement

    Learn more about this trial

    IV Paracetamol, Dexketoprofen or Morphine for the Treatment of Low Back Pain

    We'll reach out to this number within 24 hrs